i think this year will see the new “mcap range” and something like over at neuron will happen. Imagine us with even a 1.5B mcap…..We still own all of our drugs (not a part of) so the move up will be phenomenal in my view. Just need a hint that efficacy is real, and that could come anytime really now as there are a few people with this RP11 drug in them now for over 8 months. The renal biomarker has me really excited, it’s the first ‘real” and “visible” thing that has to shift the dial if it is true. Eye stuff is a bit “slow” as proof. But I will take slow over no. As for renal proof, we are a way off that yet, but at least its sometime next year. Remember if the renal candidate gets proved effective thats eventually 10B revenue US forever……try doing your PE calcs against even half of that… Once again, a first drug for PCK disease, and a database of customers. And those special tradeable certificates to boot.
Worst case they will do a sophis for another 20mill or so , just to get a bit further along. At least we are not 5c anymore.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)